barriers to glp-1 medication prescription Weight Loss NYC GLP-1s still unavailable in lower-income

This is often done to disguise missed holding times or to make re-testing appear as if it occurred on the original date

Triple-Hormone-Receptor Agonist Retatrutide for Obesity A Phase 2 Trial

However, like any treatment, there may be long-term side effects to consider

So we have Hinge Health

10.3390/ijms21072351 53 RenX.SunL.WeiL.LiuJ.ZhuJ.YuQ.et al (2020)

An analysis published this week in JAMA Internal Medicine found that most participants in a clinical trial who were assigned to stop taking tirzepatide (Zepbound from Eli Lilly) not only regained significant amounts of the weight they had lost on the drug, but they also saw their cardiovascular and metabolic improvements slip away